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Aims: The aim of this study is to investigate the clinical and laboratory characteristics of nonalcoholic 
fatty liver disease (NAFLD) in a referral center of pediatrics in the northwest of Iran.
Methods: In this cross-sectional study all subjects aged between six months to 15 years that 
were referred to the sonography unit, were investigated for fatty liver from March 2005 to August 
2006. Patients with fatty liver change underwent detailed clinical and laboratory evaluation.
Results: From 1500 children who were investigated, 34 subjects with sonographic evidence 
of fatty liver were enrolled in this study (2.3%). The mean age was 6.53 ± 3.07 years. Elevated 
aspartate aminotransferase and alanine aminotransferase was detected in 38.2% and 47.1% of 
patients, respectively. The mean level of cholesterol was 461 ± 182.23 mg/dl and 94.1% of 
patients had hypercholesterolemia. Total cholesterol level and serum aminotransferase levels 
had a significant positive correlation with severity of fatty liver (p  0.05). Mean body mass 
index was significantly higher in patients with severe fatty liver (p  0.05).
Conclusion: The epidemiology of pediatric NAFLD should inform future attempts to develop 
evaluated screening protocols. Moreover, these data should guide efforts to delineate the patho-
physiology of fatty liver in children.
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Introduction
Although nonalcoholic fatty liver disease (NAFLD) had long been recognized as a frequent 
clinical entity, only recently has its importance as a potential cause of progressive and 
severe liver disease has been fully understood.1,2 The term ‘nonalcoholic steatohepatitis’ 
(NASH) is used when a fatty liver has progressed to a stage that includes inflammation 
(steatohepatitis) and scarring (steatonecrosis) of the liver. Unlike fatty liver, NASH is 
not considered a harmless condition, but rather a liver disease with the potential to cause 
cirrhosis, liver failure, and liver cancer.1–4 NAFLD is an increasingly recognized common, 
silent, and underdiagnosed syndrome. Patients are asymptomatic in early stages of the 
disease.5 But when the disease progresses and includes inflammation, steatohepatitis 
begins to progress, leading to the development of irreversible sequels.1,2
There are some challenges in determining the prevalence of NAFLD. Diagnosis 
requires liver biopsy, which is not feasible in a population-based study. Therefore, most 
studies use serum aminotransferase evaluation as a surrogate marker for fatty liver disease, 
ideally in conjunction with a negative marker for other types of fatty liver disease.
Imaging techniques such as ultrasonography have been helpful in diagnosis and 
assessing nonalcoholic fatty liver and steatosis with a specificity and sensitivity more 
than 90%.6 NASH may be more severe in children from certain ethnic groups such as Therapeutics and Clinical Risk Management 2009:5 372
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Hispanics and Asians.7 We have no documented information 
about fatty liver in Iranian children. The aim of this study is 
to investigate the clinical and laboratory characteristics of 
NAFLD in a referral center of pediatrics in the northwest 
of Iran.
Materials and methods
This study was performed for evaluation by sonography of 
fatty liver among children in Tabriz, Iran. This study was 
approved by the institution’s Ethics Committee. All children 
aged between six months to 15 years, who came on out-
patient visits for routine follow-up or growth evaluation and 
vaccination between March 2005 and August 2006, were 
enrolled on a voluntary basis after informed consent.
A trained hepatologist and sonographist evaluated 
abdominal ultrasonographic findings. Ultrasonography was 
done with a 3–7 mHz transducer and a high-resolution B 
mode scanner (Multi Frequency Convex Abdominal Trans-
ducer; Itochu Corporation, Tokyo, Japan). We evaluated 
four ultrasonographic findings, including hepatorenal echo 
contrast, bright liver, deep attenuation, and vessel blurring.8 
The diagnosis of hepatorenal echo contrast was based on 
ultrasonographic contrast between the hepatic and right 
renal parenchyma at the right intercostals sonogram in the 
mid axillary line. The diagnosis of bright liver was based on 
abnormally intensive, high echoes arising from the hepatic 
parenchyma, and was graded on a three-grade scale as mild, 
moderate, or severe in accordance to intensity.8,9 Patients who 
had fatty liver in ultrasonographic evaluation were enrolled 
in this study.
Subjects with history of known liver disease including 
viral, metabolic, genetic, and autoimmune liver disease and 
patients with history of hepatotoxic drug intake (valproate, 
tetracycline, methotrexate, amiodorone, and prednisolone) 
and total parenteral nutrition were excluded before sono-
graphic evaluation. Patients who had fatty liver with evidence 
of an underlying disease that could have caused secondary 
obesity such as leukemia, hypothyroidism, and nephrotic 
syndrome were excluded.
Patients with fatty liver change in sonography underwent 
detailed evaluation for viral, metabolic, and autoimmune 
hepatitis in Tabriz Medical University laboratory center. 
We surveyed hepatitis B and C virus antibody in all patients 
with fatty liver.
All subjects with fatty liver had blood samples taken in the 
morning after an overnight fasting for measurement of serum 
glucose, transaminases, total cholesterol, high-(HDL) and 
low-density lipoprotein (LDL) cholesterol and triglycerides. 
Elevated liver tests defined as aspartate aminotransferase 
(AST) or alanine aminotransferase (ALT) levels more than 
1.5 times above normal values (5–45 IU/L) for age.
Patients with fatty liver who were found to have a chronic 
liver disease including alpha-1-antitrypsin deficiency, Wilson’s 
disease, autoimmune and viral hepatitis were excluded. In the 
remaining patients, body mass index (BMI) was calculated.
All data was gathered in a designed form containing demo-
graphic features, past medical history, drug history, results of 
physical exam and laboratory tests, and were analyzed by SPSS 
software (version 14 for Windows; SPSS Inc., Chicago, IL, 
USA). Chi-square and t-test were used for analysis. A p value 
less than 0.05 was considered significant.
The study was approved by the University Review Board, 
and informed consent was obtained from the subjects and 
their parents prior to assessment.
Results
From 1500 children who were investigated for NAFLD, 
after excluding patients with underlying diseases mentioned 
above, the prevalence of NAFLD was 2.3%. None of the 
patients had diabetes mellitus.
The mean age of 34 subjects was 6.53 ± 3.07 years (range: 
six months to 15 years). Most (64.9%) were male. There was 
no significant correlation between gender and sonographic 
report of fatty change or between the grade of fatty change and 
gender (χ2 = 1/40, df = 1; p = 0.236). Prevalence of fatty liver 
increased with age, ranging from 0.7% for ages 2–4 years up 
to 17.3% for ages 12–15 years. In the physical examination, 
mild hepatomegaly was the most frequent clinical finding 
and was detected in 48.6% of patients with fatty liver. 28% 
of study groups had some complaints such as fullness of 
epigastric area (11%), mild right upper quadrant pain (8%), 
and 9% complained of early satistification. From 34 children 
with fatty liver, 18 patients (52.9%) had mild, 13 patients 
(38.2%) had moderate, and three (8.8%) had severe degrees of 
fatty liver. Elevated AST was detected in 13 patients (38.2%) 
with a mean of 73 ± 120.73 U/lit (range 17–716). Elevated 
serum ALT levels was found in 16 patients (47.1%) with a 
mean of 63 ± 74.32 U/lit (range 3–341). A strong positive 
correlation was demonstrated between ultrasonic severity of 
fatty liver and elevation of ALT and AST (p  0.05).
The mean level of cholesterol was 461 ± 182.23 (range: 
91–950). Only two patients had normal total cholesterol 
(5.9%) and the other 32 patients (94.1%) had cholesterol 
levels more than normal value. Total cholesterol level had a 
significant correlation with severity of fatty liver (χ2 = 9.53, 
df = 2; p = 0.008).Therapeutics and Clinical Risk Management 2009:5 373
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Thirty patients (88.2%) had high HDL levels (mean: 
98 ± 54.49; range: 24–230 mg/dl), 29 patients (87.90%) had 
high LDL levels (mean: 308 ± 146.48; range: 38–629 mg/dl) 
and 44.1% of our patients had triglyceride levels more 
than 250 mg/dl (mean: 260.56 ± 106.74; range: 40–458) 
(Table 1).
Serum triglycerides and fasting plasma sugar were signif-
icantly higher in girls than in boys (p  0.05), but there was 
no significant relation between these parameters with grading 
of fatty liver (p  0.05).
Mean of BMI in patients with fatty liver were 22.35 ± 4.92 
(range: 15.6 to 33.3). Mean BMI was significantly higher in 
patients with severe fatty liver (33 ± 28) compared to patients 
with moderate and mild fatty liver structure (p  0.05).
Discussion
We believe that the current study is the first to determine 
the prevalence and identify the characteristics of fatty liver 
in pediatric population in our region. Histological features 
of fatty liver include steatosis alone or with combination of 
mixed inflammatory cell infiltration, hepatocyte ballooning 
and necrosis, Mallory’s hyaline and fibrosis although portal-
based injury is commonly seen in children.10,11
In a study of school-aged children in northern Japan, 
overall prevalence of fatty liver was 2.6% by sonography 
with male dominancy. However, such prevalence has been 
found to be 10%–35% in obese children.3 Another study 
from Turkey showed that prevalence of fatty liver detected 
by sonography was 11.8% and elevated ALT and AST levels 
were found in 4.6%.11 In this study elevated serum AST was 
detected in 38.2% and ALT in 47.1% of our patients.
In a ultrasound-based study of Italian obese children, 
fatty liver was present in 38 (53%) children, severe in nine, 
moderate in 16, and mild in 13 patients and elevated serum 
aminotransferase were present in 25%.7
The exact prevalence of NASH/NAFLD is not well 
established. Information on its prevalence among children is 
scanty. Pooling data from studies were done mainly in medical 
centers and the prevalence of NAFLD in obese children has 
been reported to range from 20% to 77%.12,13 Investigators 
have used various methods to determine the prevalence of 
NAFLD in childhood. Ultrasound of the liver has been found 
to be a good screening tool for assessment of the degree of fat 
in the liver, but it does not correlate well with the degree of 
fibrosis. Joseph and colleagues reported a sensitivity of 89% 
and specificity of 93% for sonography in detecting steatosis, 
but a sensitivity of 77% and specificity of 89% in detecting 
fibrosis in the liver, respectively.14 The sensitivity and speci-
ficity of computed tomography (CT) and magnetic resonance 
imaging (MRI) varied from 54%–93% and 87%–97%, respec-
tively according to the protocol followed.15 However CT scans 
or MRI are very costly and not feasible as routine work-up of 
suspected NAFLD. Liver biopsy remains the gold standard 
for diagnosis of steatosis and degrees of fibrosis. No imaging 
method is able to distinguish between simple steatosis and 
NASH and/or indicate the stage of fibrosis.
A study by Franzese and colleagues found that children 
with fatty liver in sonography had high BMI values, but could 
not demonstrate such a relationship.7
The epidemiology of pediatric NAFLD should inform 
future attempts to develop evaluated screening protocols. 
Moreover, these data should guide efforts to delineate the 
pathophysiology of fatty liver in children and adolescents.
Conclusion
Our study demonstrates that children with fatty liver may be 
asymptomatic or may present with nonspecific complaints. 
We found a significant correlation between elevation of ALT 
and AST, high levels of serum total cholesterol, and severity 
of obesity with grading of fatty liver.
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